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A B S T R A C T
GM1 gangliosidosis is an autosomal recessive neurodegenerative disorder caused by the deficiency of lysosomal β-galactosidase (β-gal) and resulting in accumulation
of GM1 ganglioside. The disease spectrum ranges from infantile to late onset and is uniformly fatal, with no effective therapy currently available. Although animal
models have been useful for understanding disease pathogenesis and exploring therapeutic targets, no relevant human central nervous system (CNS) model system
has been available to study its early pathogenic events or test therapies. To develop a model of human GM1 gangliosidosis in the CNS, we employed CRISPR/Cas9
genome editing to target GLB1 exons 2 and 6, common sites for mutations in patients, to create isogenic induced pluripotent stem (iPS) cell lines with lysosomal β-gal
deficiency. We screened for clones with< 5% of parental cell line β-gal enzyme activity and confirmed GLB1 knockout clones using DNA sequencing. We then
generated GLB1 knockout cerebral organoids from one of these GLB1 knockout iPS cell clones. Analysis of GLB1 knockout organoids in culture revealed progressive
accumulation of GM1 ganglioside. GLB1 knockout organoids microinjected with AAV9-GLB1 vector showed a significant increase in β-gal activity and a significant
reduction in GM1 ganglioside content compared with AAV9-GFP–injected organoids, demonstrating the efficacy of an AAV9 gene therapy-based approach in GM1
gangliosidosis. This proof-of-concept in a human cerebral organoid model completes the pre-clinical studies to advance to clinical trials using the AAV9-GLB1 vector.
1. Introduction
GM1 gangliosidosis is an autosomal recessive neurodegenerative
disorder caused by deficiency of the lysosomal hydrolase β-galactosi-
dase (β-gal) [1]. Mutations in the gene GLB1 result in reduced or absent
activity of β-gal, leading to lysosomal accumulation of GM1 ganglio-
side, a membrane glycosphingolipid important for neuronal function
[2]. The estimated incidence of GM1 gangliosidosis is 1 in
100,000–200,000 live births [3,4],. Currently no effective treatments
are available. The disease is a continuum, with decreasing residual β-
gal activity leading to increasing clinical severity and where the amount
of residual enzyme is determined by the specific GLB1 mutation(s) [5].
The continuum has been historically classified into three types. Type I
(OMIM 230500), Type II (OMIM 230600), and Type III (OMIM 230650)
and Type II has been recently subdivided into late-infantile (IIa) and
juvenile (2b) subtypes [1].
GM1 gangliosidosis is predominantly a central nervous system
(CNS) disorder and has been difficult to study in vivo. Several naturally
occurring animal models recapitulate the phenotype to varying degrees,
including cat [6–9], sheep [10–12], dog [13–16], calves [17], and bears
[18], as well as engineered mouse models [19–22]. Phenotypes pre-
sented by these animal models include GM1 ganglioside storage in
neurons, progressive neurologic dysfunction, and a shortened lifespan.
Although these models have been beneficial in understanding disease
pathogenesis and exploring potential therapies, they lack human-spe-
cific features of the disease. Thus far, human studies have been gen-
erally limited to cranial imaging and post-mortem end-stage histologic
analyses.
https://doi.org/10.1016/j.ymgmr.2019.100513
Received 22 May 2019; Accepted 28 August 2019
Abbreviations: 4MU, 4-methylumbelliferyl; AAV, adeno-associated virus; AAV9, AAV serotype 9; β-gal, β-galactosidase; BSA, bovine serum albumin; CNS, central
nervous system; CPB, citrate phosphate buffer; EB, embryoid body; GFP, green fluorescent protein; hiPSC, human induced pluripotent stem cells; HPTLC, high-
performance thin-layer chromatography; iPS, induced pluripotent stem; PBS, phosphate-buffered saline; RT-qPCR, real-time quantitative polymerase chain reaction;
SD, standard deviation; X-gal, 5-bromo-4-chloro-3-indolyl-β-D-galactopyranoside
⁎ Corresponding author.
E-mail address: ctifft@nih.gov (C.J. Tifft).
1 C.J. Tifft and R.L. Proia equally supervised this work.
Molecular Genetics and Metabolism Reports 21 (2019) 100513
2214-4269/ Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/BY-NC-ND/4.0/).
T
Human induced pluripotent stem cells (hiPSCs) are a powerful tool
to model human disorders. They can be readily differentiated into re-
levant cell types and thus provide an in vitro model of disease [23]. By
combining the versatile nature of hiPSCs with the CRISPR/Cas9 genome
editing technique [24], it is possible to create isogenic hiPSC lines to
analyze the effects of a monogenic disorder while minimizing differ-
ences in genetic backgrounds. Since the first reports in 2013 [25],
steady advances have been made in differentiating hiPSCs into three-
dimensional cerebral organoids to study neurodevelopment as well as
neurologic and neuropsychiatric disorders [26]. Initial studies to de-
velop a model system for microcephaly have expanded to include other
disorders of early brain development, including lissencephaly and
cortical folding. Genetic syndromes and monogenic disorders, autism
spectrum disorder, and environmental insults to the developing brain
(such as Zika virus) have also been modeled (reviewed in [26]).
Despite the lack of effective treatments for GM1 gangliosidosis,
several studies have investigated the use of adeno-associated virus
(AAV)-mediated gene therapy for the disease. Intracranial injections of
AAV encoding lysosomal β-gal in mouse and cat models reduced GM1
ganglioside content throughout the CNS, extended stable behavioral
functions, and increased lifespan [27–30]. GLB1 delivered in-
travenously using AAV serotype 9 (AAV9) in GM1 gangliosidosis mice
has been shown to traverse the blood-brain barrier, producing wide-
spread transduction of multiple brain regions, reduced GM1 ganglioside
storage in the CNS, and improved survival [31]. Here we describe a
GLB1 knockout hiPSC line generated using CRISPR/Cas9 genome
editing, demonstrate the advantage of a fluorescence-based enzyme
assay to screen large numbers of clones for targeted genome editing,
establish an in vitro human GLB1 knockout cerebral organoid model of
GM1 gangliosidosis, and demonstrate the efficacy of AAV9-GLB1 gene
therapy in reducing GM1 ganglioside content in GLB1 knockout cere-
bral organoids.
2. Results
2.1. Generation of a GLB1 knockout hiPSC line
We used hiPSCs from an unaffected individual, referred to as the
parental cell line, to develop isogenic GLB1 knockout cell lines using
CRISPR/Cas9 genome editing. Because exons 2 and 6, along with exon
15, of GLB1 contain the majority of reported nonsense and missense
mutations in human GM1 gangliosidosis patients [3], we designed
sgRNAs each to exon 2 (Exon 2-1) and exon 6 (Exon 6-1 and 6-2). The
hiPSCs were transfected with a plasmid vector carrying Cas9 and one of
the sgRNAs, and successfully transfected cells were selected with pur-
omycin. Colonies that maintained undifferentiated morphology were
assayed for enzyme activity using a 4-methylumbelliferyl (4MU) sub-
strate specific for β-gal (expressed as a percent of activity of the par-
ental cell line). Less than 5% activity was set as the criteria for suc-
cessful genome editing. In total, 107 colonies were screened: 44
colonies transfected with sgRNA Exon 2-1, 44 colonies transfected with
sgRNA Exon 6-1, and 19 colonies transfected with sgRNA Exon 6-2
(Fig. 1A). Most of the colonies (78%) had ≤10% of the enzyme activity
found in the parental cell line. Two colonies produced by each guide
with< 5% activity and undifferentiated morphology, were selected for
sequencing confirmation of GLB1 mutations. One clone (asterisk,
Fig. 1A) contained bi-allelic GLB1 mutations that were targeted by
sgRNA Exon 6-2 (i.e., a one base-pair insertion and a one base-pair
deletion [Fig. 1B]); this clone was chosen for further studies.
Both GLB1 mutations in the selected clone result in premature stop
codons and are predicted to encode truncated proteins (Fig. 1C). To
evaluate the validity of the GLB1 knockout hiPSC line as an isogenic
model to the parental cell line, we measured GLB1mRNA expression by
real-time quantitative polymerase chain reaction (RT-qPCR) and se-
quenced potential Cas9 off-target sites. Using a 3′-specific TaqMan
probe to GLB1, we determined that GLB1 mRNA expression was
negligible in the GLB1 knockout line compared with the parental cell
line (Fig. 1D). The top five predicted off-target sites (CRISPRtool, his-
torically: http://crispr.mit.edu) were sequenced for evidence of off-
target editing and none were found.
2.2. Generation and characterization of GLB1 knockout cerebral organoids
with β-galactosidase deficiency and GM1 ganglioside storage
Cerebral organoids were generated from the parental cell line,
henceforth referred to as the isogenic control, and the selected CRISPR
edited hiPSCs by embedding cell-aggregated embryoid bodies (EBs) in
the artificial extracellular matrix, Matrigel, to promote radial growth,
then maintained in bioreactors [32] (Fig. S1). Histologic evaluation of
control organoids showed ventricle-like structures lined with cilia, (Fig.
S2A and B), and immunohistochemistry revealed regions of neural
progenitors (SOX2) and astrocytes (GFAP) within the organoids (Fig.
S2C and D).
In GM1 gangliosidosis, mutations in the GLB1 gene result in re-
duction or loss of lysosomal β-gal enzyme activity, leading to the ac-
cumulation of the GM1 ganglioside in lysosomes. To analyze GM1
ganglioside accumulation in organoids over time, im-
munohistochemistry was performed using an anti-GM1 monoclonal
antibody (validated in Fig. S3) on GLB1 knockout and isogenic control
organoids at 5-week intervals. At 20 weeks in culture, a significant in-
crease of GM1 ganglioside storage in GLB1 knockout organoids com-
pared to the isogenic control organoids was detectable by immuno-
fluorescence (Fig. 2A and B). The fluorescent signals from anti-GM1
ganglioside and anti-LAMP1 (lysosomal marker) immunostaining of
GLB1 knockout organoids were co-localized, indicating that the GM1
ganglioside storage occurred in lysosomes (Fig. S4). X-gal staining of
whole cerebral organoids at 15 weeks showed decreased β-gal activity
throughout the GLB1 knockout organoids compared with the isogenic
control organoids from the parental line (Fig. 2C).
Ganglioside content in the cerebral organoids was determined by
high-performance thin-layer chromatography (HPTLC) (Fig. 3A); GM1
ganglioside content was significantly elevated in the GLB1 knockout
organoids at 10 and 20weeks, but not earlier, suggesting a progressive
accumulation of GM1 when compared with isogenic control organoids
(Fig. 3B).
2.3. Reduction in GM1 ganglioside content in GLB1 knockout cerebral
organoids following AAV9-GLB1 injection
AAV9-GLB1 was injected into the center of 10-week-old GLB1
knockout cerebral organoids and β-gal activity and GM1 ganglioside
content were analyzed 5weeks after injection. Controls included un-
injected GLB1 knockout organoids, GLB1 knockout organoids injected
with an equivalent titer of AAV9-green fluorescent protein (AAV9-GFP),
and uninjected isogenic control organoids. All GLB1 knockout orga-
noids used were from the same culture to minimize variability. Relative
β-gal activity (expressed as a percent of activity of isogenic controls)
was significantly increased in AAV9-GLB1–injected organoids com-
pared with the uninjected and AAV9-GFP–treated organoids (Fig. 4A
and B). GM1 ganglioside content was significantly decreased in AAV9-
GLB1–treated organoids compared with AAV9-GFP–treated organoids
when examined by both immunohistochemistry (Fig. 4C and D) and
HPTLC analysis (Fig. 4E and F).
3. Discussion
Since their initial description in 2013, the study of stem cell-derived
cerebral organoids has expanded rapidly [25] and has filled an im-
portant niche in the study of genetic and acquired CNS disorders [26].
Using organoids produced by CRISPR/Cas9 genome editing and com-
paring the edited organoids to isogenic controls, it is now possible to
study disease pathogenesis flowing from mutations in a single gene.
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GM1 gangliosidosis is a monogenic, progressive, uniformly fatal
neurodegenerative disorder with no effective therapy, thereby limiting
treatment to supportive care. Acquiring relevant human primary tissue
to verify findings in animal model systems is extremely difficult. Here,
we have leveraged the advances in CRISPR/Cas9 editing and hiPSC-
based three-dimensional cultures to provide a human CNS model
system for GM1 gangliosidosis to investigate the molecular pathogen-
esis of and therapy for this devastating disease. Through isolation of a
GLB1 knockout hiPSC line and establishment of GLB1 knockout cere-
bral organoids, we established an in vitro human GM1 gangliosidosis
model system that demonstrated the hallmarks of the disease (i.e., loss
of β-gal enzyme activity and progressive storage of GM1 ganglioside).
Quantitative enzyme analysis is one of the most widely used
methods for diagnosing lysosomal storage disorders in clinical labora-
tories. Activity is usually determined using a fluorescent, 4MU substrate
specific to the enzyme of interest. We applied this simple enzymatic
detection method for screening and identification of hiPSC clones that
were successfully targeted by our CRISPR/Cas9 sgRNAs to introduce
GLB1 mutations and therefore negate β-gal activity. Generally, clones
are first selected after Sanger sequencing of PCR-amplified genomic
DNA [24], but this method is time-consuming, especially if the fre-
quency of successfully targeted editing is low. We were able to rapidly
screen a large number of clones using the enzymatic assay and then
sequence only those found to be essentially devoid of enzyme activity.
This procedure is both time and cost efficient. Although sequencing is
still required to confirm resulting mutations, the screening greatly re-
duces the pool of candidate clones before that step. Because 4MU
substrates are available for most lysosomal enzymes, this method would
be widely applicable to other lysosomal diseases [33].
In the current study, GLB1 knockout cerebral organoids
demonstrated GM1 ganglioside accumulation detectable by HPTLC
beginning as early as 10weeks in culture (Fig. 4) and visible histolo-
gically at 20 weeks (Fig. 3). Using a similar system, our lab has de-
monstrated that cerebral organoids derived from an infantile Sandhoff
disease (GM2 gangliosidosis) patient show GM2 ganglioside accumu-
lation beginning at 4 weeks [38]. Whereas GM1 ganglioside is an
abundant constituent of neuronal plasma membranes [34], GM2
ganglioside is an intermediate in the ganglioside metabolic pathway
and is present in low quantities in normal human brain [35]. This low
background may allow earlier detection of abnormal accumulation in
the Sandhoff organoids [36]. The discrepancy in the timing of gang-
lioside accumulation in the Sandhoff and GLB1 knockout organoids
may be also be related to intrinsic differences in the recycling and
metabolism of the two different gangliosides.
Lysosomal storage of GM1 and GM2 ganglioside in GM1 and GM2
gangliosidosis, respectively, has been demonstrated in human fetuses as
early as the second trimester [35,37]. Cerebral organoids have been
shown to model the human fetal neocortex [34,36,38]. In Sandhoff
disease organoids, the enzyme deficiency and GM2 ganglioside accu-
mulation impaired neuronal differentiation in developmental parallel
to the early fetal period [36]. Given that GM1 ganglioside storage also
begins in fetal life in infantile GM1 gangliosidosis [39], neuronal dis-
turbances might also be expected during fetal development, suggesting
that effective therapy for infantile onset disease may require in utero
treatment (ref).
Intravenous gene therapy with AAV9-GLB1 has been effective in
treating murine and feline models of GM1 gangliosidosis [31]. Here,
treating GLB1 knockout cerebral organoids with comparable doses of
AAV9-GLB1 vector significantly increased β-gal enzyme activity and
significantly decreased GM1 ganglioside content, indicating its efficacy
Fig. 1. GLB1 knockout clone screening and mutation con-
firmation.
(A) Screening of CRISPR/Cas9-edited clones using a β-gal
enzyme activity assay. Three different sgRNAs, one targeting
exon 2 (Exon 2-2) and two targeting exon 6 (Exon 6-1 and
Exon 6-2), were designed and used for editing the GBL1 gene
in hiPSCs. The resulting 107 colonies were screened for β-gal
enzyme activity and plotted: 44 for sgRNA Exon 2-1 (blue
bars), 44 for sgRNA Exon 6-1 (orange bars) and 19 for sgRNA
Exon 6-2 (green bars). Of those, two clones produced by each
sgRNA, with undifferentiated morphology and< 5% enzyme
activity (compared with the parental cell line [value set at
100%]) were sequenced. An asterisk marks the clone selected
for further experiments. (B) Characterization of the mutations
in the selected knockout hiPSC clone. The reference sequence
of the GLB1 gene in the edited region is shown. Allele 1
contains a 1 base-pair insertion, an A, and allele 2 contains a 1
base-pair deletion, both highlighted in yellow. Boxes outline
the location of the protospacer adjacent motif (PAM) se-
quence. (C) Predicted proteins resulting from the mutations in
alleles 1 and 2 compared with β-gal protein domains(top;,
adapted from [48]). Both mutations are predicted to produce
truncated proteins prior to E368, an important catalytic nu-
cleophile. (D) Relative mRNA expression of GLB1 normalized
to GAPDH. KO, GBL1 knockout organoids. Data represent the
mean ± standard deviation (SD), n=3 for each line)
(⁎⁎p < .01, t-test analysis between control and KO values).
(For interpretation of the references to colour in this figure
legend, the reader is referred to the web version of this ar-
ticle.)
Y.L. Latour, et al. Molecular Genetics and Metabolism Reports 21 (2019) 100513
3
in a relevant human model system. This method of testing therapeutics
could be applied to other monogenic CNS disorders and provides a
bridge between animal models and clinical trials.
The pathogenesis of many lysosomal storage disorders has also been
shown to involve the activation of bone marrow-derived microglial
cells [40]. Recently described “assembloids” composed of both cerebral
and microglial organoids may be an important next step in elucidating
pathogenesis in these disorders [41]. So too, vascularization of cerebral
organoids as recently demonstrated [42,43] may facilitate prolonged
growth and differentiation of organoids and may provide further clues
to the mechanism of disease.
In conclusion, we have generated a human CNS model of GM1
gangliosidosis using GLB1 knockout hiPSCs differentiated to cerebral
organoids grown in parallel with isogenic control cerebral organoids.
We have demonstrated that the GLB1 knockout organoids recapitulate
the hallmark phenotype of GM1 ganglioside storage that can be re-
versed with AAV9-GLB1 gene therapy. This demonstration was the final
step in the pre-clinical development of the AAV9-GLB1 vector for a
phase 1/2 clinical trial for children with type II GM1 gangliosidosis
(NCT03952637).
4. Materials and methods
4.1. hiPSC culture
The unaffected parental hiPSC line was obtained from Alstem
(Episomal, HFF: #iPS11), and was verified pluripotent and
contamination free. It is a footprint-free iPS cell line derived from
human foreskin fibroblasts by ectopic expression of OCT4, SOX2, KLF4,
and cMYC genes using episomal plasmids. hiPSCs were maintained
feeder-free in mTeSR1 (STEMCELL Technologies, 05850) on Matrigel
(Corning, 354277)-coated plates. To prevent cell death, 10 μM Y-27632
(STEMCELL Technologies, 72304) was added to culture media after
each passage or detachment.
4.2. Genome editing using CRISPR/Cas9
sgRNAs were designed with the CRISPRtool (historically: http://
crispr.mit.edu) to maximize on-target binding and minimize potential
off-target editing. Two sgRNAs were designed for exons 2 and 6 of
GLB1: sgRNA Exon 2-1: CGGTCCTTCCAGTAGAAGCG; sgRNA Exon 2-2:
CTTCCTGAGATGTAGCGAAA; sgRNA Exon 6-1: CAAAGTCCACCGTGG
TGTAG; and sgRNA Exon 6-2: GAAGCGCTTTCGCCACCATC. sgRNAs
were cloned into the CRISPR-Cas9 plasmid, pSpCas9(BB)-2A-Puro
(PX459), a gift from Feng Zhang (Addgene, Plasmid #48139) [24]. The
hiPSCs from two wells of a 6-well plate at 70% confluency were de-
tached with 1:1 Accutase:phosphate-buffered saline (PBS) and after
that, combined, filtered using a 40 μm cell strainer to obtain a uniform
cell suspension and pelleted. Cells were electroporated with 20 μg of
CRISPR-Cas9 plasmid with inserted sgRNA, using the Human Stem Cell
Nucleofector Kit 1 and the Nucleofector II Device (Lonza). Selection for
edited cells started 24 h post-transfection by treating with 0.5 μg/ml
puromycin for 48 h. The hiPSCs were later maintained in media con-
taining a 1:1 ratio of fresh mTeSR1 and filtered, conditioned media
Fig. 2. GM1 Ganglioside Storage and β-Gal Enzyme
Activity in GLB1 knockout Cerebral Organoids.
(A) Representative images of isogenic control and
GLB1 knockout cerebral organoids harvested at 5,
10, 15, and 20 weeks and stained with anti-GM1
ganglioside (green) and anti-β3 tubulin (red) anti-
bodies. Nuclei were visualized with DAPI staining
(blue). Arrows indicate areas of GM1 storage. Scale
bars: white, 500 μm; yellow, 10 μm. (B)
Quantification of GM1 fluorescent signal normalized
to DAPI of GLB1 knockout organoids compared with
isogenic control organoids. Data represent the mean
relative GM1 expression± SD, n≥3 for both con-
trol and knockout organoids at each time point
(⁎⁎⁎p < .001, two-way Anova analysis between
control and knockout values). (C) X-gal staining of
isogenic control and GLB1 knockout cerebral orga-
noids harvested at 15 weeks. Blue staining on the
organoids indicates β-gal activity. Scale bars,
500 μm. (For interpretation of the references to
colour in this figure legend, the reader is referred to
the web version of this article.)
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collected from established hiPSCs cultures, until stable colonies were
formed.
4.3. Clone screening
Individual hiPSC colonies were picked, cultured in individual 48-
well plates, and screened for β-gal activity as previously described [44]
to determine whether editing occurred. Briefly, hiPSC were lysed in
0.1M citric buffer (pH 4.2) containing 0.1% Triton X-100 on ice for
30min. β-gal activity was measured with 4mM 4-methylumbelliferyl
(4MU) β-D-galactopyranoside (Sigma-Aldrich) and was normalized
with β-hexosaminidase activity using 20mM 4MU N-acetyl-β-D-gluco-
saminide (Sigma-Aldrich). Parental, untransfected hiPSCs were sub-
jected to the same analysis to serve as a reference value for normal
(100%) β-gal activity. Both reactions were performed at 37 °C for
30min and stopped with 200 μl 0.2M glycine (pH 9.6). Fluorescence
was measured on a Perkin Elmer Victor 1420 Multilabel Counter (ex-
citation: 360nm, emission: 446nm).
To validate the targeted mutation sites, genomic DNA was isolated
and PCR-amplified using primers to encompass each exon (Table S1)
and cloned into a TOPO-TA sequencing vector (Invitrogen, 45-0030).
DNA was isolated from 10 bacterial colonies and analyzed by Sanger
sequencing (outsourced to Eurofins Genomics).
4.4. Off-target screening
The top five off-target sequences were extracted from the
CRISPRtool (historically: http://crispr.mit.edu) when designing the
guides. Genomic DNA was isolated and PCR-amplified using primers to
encompass each off-target site (Table S2). PCR products were purified
using the Qiagen QIAquick PCR Purification Kit (Qiagen, 28106) and
sequenced.
4.5. Multiplex RT-qPCR
Total RNA was extracted from hiPSCs using the RNeasy Plus Micro
kit (Qiagen, 74034). cDNA was synthesized using the SuperScript® IV
First-Strand Synthesis System (Invitrogen, 18091050) following the
manufacturer's instructions. Taqman probes (GLB1 [Hs01035168]-FAM
and GAPDH [Hs02758991_g1]-VIC) were purchased from Thermo
Fisher Scientific. The PCR reaction was initialized with 2min at 50 °C
and 10min at 95 °C followed by 40 cycles of 15 s at 95 °C and 60 s at
60 °C.
4.6. Generation of cerebral organoids
Cerebral organoids were generated using the parental (isogenic
control) and GBL1-edited hiPSC lines as described previously [25,32],
with the following minor modifications. Single-cell suspensions were
produced by detaching cells with Accutase for 10min at 37 °C. Ag-
grewell™400 plates (STEMCELL Technologies) and Aggrewell™ EB
Formation Medium (STEMCELL Technologies) were used following the
manufacturer's protocols during days 0–3 of EB formation. On days
2–10, EBs were transferred to 24-well ultra-low adherence plates and
cultured in neural induction media, beginning on day 5, with media
changes every other day. The resulting organoids were embedded in
Matrigel matrix droplets on day 10 and grown in neural differentiation
media supplemented with B-27 without vitamin A (B-27-) for 4 days in
10mm dish. After this, organoids were grown in neural differentiation
media supplemented with B-27 plus vitamin A (B-27+)in suspension in
125ml spinner flasks, on a low-speed microstirrer (Wheaton) at 25 rpm
in a 5% CO2 tissue-culture incubator. Organoids were harvested at
weeks 5, 10, 15, and 20 for analysis.
4.7. X-gal staining
Whole cerebral organoids were stored at −80 °C and, without
thawing, fixed in 2% glutaraldehyde/2% formaldehyde in PBS for
10min at room temperature. Organoids were incubated in ice-cold ci-
trate phosphate buffer (CPB, pH 4.2) for 20min, then incubated in X-gal
working solution containing 40mg/ml 5-bromo-4-chloro-3-indolyl-β-D-
galactopyranoside (X-gal, Invitrogen, 15520-018), 20mM K3Fe(CN)6
(Sigma-Aldrich), 20mM K4Fe(CN)6 (Sigma-Aldrich), 0.02% IGEPAL
(Sigma-Aldrich), 0.01% deoxycholic acid (Sigma-Aldrich), and 2mM
MgCl2 (Mallinckrodt) in CPB at 37 °C for 30min to 2 h. The tissue was
rinsed first with CPB and then with PBS, and imaged using a dissecting
microscope.
4.8. Organoid β-galactosidase activity
Whole organoids were stored at −80 °C and, without thawing,
homogenized in 0.1M citric buffer (pH 4.2) containing 0.1% Triton X-
100 and placed on ice for 30min. β-gal activity was measured with
4mM 4MU β-D-galactopyranoside (Sigma-Aldrich) and was normalized
with β-hexosaminidase activity using 20mM 4MU N-acetyl-β-D-gluco-
saminide (Sigma-Aldrich). Isogenic control organoid lysate was sub-
jected to the same analysis to serve as a reference value for normal
(100%) β-gal activity. Both reactions were performed at 37 °C for
30min and stopped with 200 μl 0.2M glycine (pH 9.6). Fluorescence
was measured on a Perkin Elmer Victor 1420 Multilabel Counter (ex-
citation: 360nm, emission: 446nm).
4.9. Histological analysis
Human fibroblasts were cultured in chamber slides and fixed in 4%
Fig. 3. GM1 Ganglioside Storage in GLB1 Knockout Cerebral Organoids.
(A) Representative HPTLC analysis of gangliosides extracted from isogenic
control and GLB1 knockout cerebral organoids harvested at 20weeks.
Gangliosides extracted from 3 pooled organoids (control and knockout) were
applied per lane. Std, Monosialogangliosides used as standards. (B)
Quantification of GM1 ganglioside content of control and GLB1 knockout or-
ganoids harvested at 10, 15, and 20weeks. GM1 content was determined by
densitometry of the HPTLC plate and normalized with the corresponding
phospholipid concentrations. Data represent mean GM1 content at each time
point relative to control content at week 10 ± SD, n=3 lanes (⁎p < .05, t-test
analysis between control and knockout values).
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paraformaldehyde in PBS at 4 °C for 15min and then washed with PBS.
Cerebral organoids were fixed in 4% paraformaldehyde in PBS at 4 °C
for 15min, washed with PBS, and then equilibrated overnight in 30%
sucrose prior to OCT compound embedding and sectioning. Frozen
OCT-embedded blocks of normal and GM1 gangliosidosis cat brain
tissue were obtained from Dr. Douglas R. Martin, College of Veterinary
Medicine, Auburn University. Frozen OCT-embedded blocks of normal
and GM1 gangliosidosis mouse brain were obtained from Dr.
Alessandra d'Azzo, St. Jude Children's Research Hospital. Fixed cells or
brain sections were incubated with PBS for 15min and permeabilized
with 0.2% Triton in PBS for 10min, washed with PBS, and then blocked
with 1% bovine serum albumin (BSA) and 5% horse serum in PBS at
room temperature for 1 h. Sections were then incubated in 1% BSA and
5% horse serum in PBS overnight with the following primary anti-
bodies: anti-GM1 ganglioside (mouse monoclonal antibody, Amsbio
clone GMB16, 1:50); anti-β3 tubulin (mouse, previously Convance,
clone TUJ1, 1:750); anti-SOX2 (rabbit, Chemicon, AB5603, 1:300);
anti-GFAP (rabbit, Abcam, ab7260, 1:500); or anti-LAMP1 (mouse,
Santa Cruz Biotechnology, H5G11, 1:200). Secondary antibodies were
goat Alexa Fluor 488- and 594-conjugates (Invitrogen, 1:500 or
1:1000). Antibody-stained cryosections were mounted with
Fluoroshield Mounting Medium with DAPI (Abcam) and observed using
a spectral confocal microscope (LSM 780; Carl Zeiss, Inc.). Fluorescent
micrographs were captured using Zen 2012 software (Carl Zeiss, Inc.).
Immunofluorescence was quantified by extracting mean fluorescence
for each colour channel using Fiji [45,46] (ImageJ) and GM1 ganglio-
side fluorescence intensity was normalized to DAPI fluorescence in-
tensity. Co-localization analysis of GM1 ganglioside and LAPM1 ex-
pression was performed using the plot profile analysis tool in Fiji on
images of organoid sections stained with antibodies against GM1
ganglioside and LAMP1. A single pixel-wide line was drawn across
areas of GM1 ganglioside signal and the intensity for GM1 ganglioside
fluorescence (green channel) and LAMP1 (red channel) along the line
were determined and plotted.
Organoids were sectioned and stained with hematoxylin eosin (H&
E) or processed for transmission electron microscopy (EM) as described
in [37].
4.10. Ganglioside extraction and purification
Total gangliosides were extracted from pooled organoids (n=3) by
mechanically disrupting the organoids in 19 volumes of chlor-
oform:methanol (2:1, v:v) and shaking for 1 h at room temperature. A
second extraction was done with half the original extraction volume
and shaking for another hour at room temperature. The two extraction
solvents were combined and dried under nitrogen. The dried lipids were
re-dissolved in chloroform:methanol (2:1, v:v) and partitioned with
0.1M KCl (1:0.2, v:v). The organic phase was reserved for phospholipid
quantitation as described previously [47] to normalize GM1 content.
The aqueous phase containing the gangliosides was de-salted using
reverse phase C18 Sep-Pak columns (Waters, WAT023590). The column
eluate containing the gangliosides was dried under nitrogen and re-
dissolved in chloroform:methanol (1:1, v:v).
4.11. HPTLC and ganglioside analysis
HPTLC was performed with pre-coated 10×20 cm, 250 μm thick
silica gel HPTLC plates (Merck). Each plate was loaded with mixed
gangliosides, including GM1, GM2, and GM3, as a reference marker
(catalogue #: 1508, Matreya). Total gangliosides extracted from pooled
cerebral organoids (n=3) were applied in 0.7 cm lanes using a 10 μl
syringe. The HPTLC plates were developed in a glass running chamber
Fig. 4. Treatment of GLB1 Knockout Cerebral Organoids with
AAV9-GLB1 Gene Therapy.
GLB1 knockout cerebral organoids were injected with AAV9-
GFP or AAV9-GLB1 at 10weeks and harvested for analysis
5 weeks later. (A) Representative X-gal staining of AAV9-
GFP–injected and AAV9-GLB1–injected organoids. Scale bars,
500 μm. (B) β-gal enzyme activity of whole cerebral organoid
lysates (compared to uninjected isogenic controls whose value
was set at 100%). Data represent the mean relative β-gal
activity± SD (n=5 organoids for each treatment);
⁎p < .05, t-test analysis). (C) Representative images of AAV9-
GFP– and AAV9-GLB1–injected organoids stained with anti-
GM1 (green) and anti-β3 tubulin (red) antibodies. Nuclei
were visualized with DAPI staining (blue). Arrows indicate
areas of GM1 storage. Scale bars: white, 500 μm; yellow,
65 μm. (D) Quantification of GM1 fluorescent signal normal-
ized to DAPI of AAV9-GLB1–injected organoids compared
with AAV9-GFP–injected organoids. Data represent mean
GM1 content normalized with DAPI ± SD, n=3 injected
organoids per treatment and 16 immunostained fields per
analysis (⁎⁎⁎p < .001, t-test analysis between AAV9-GFP-in-
jected and AAV9-GLB1-injected organoids). (E)
Representative HPTLC plate of gangliosides extracted from
AAV9-GFP–injected and AAV9-GLB1–injected organoids.
Gangliosides extracted from 3 organoids were applied per
lane for AAV9-GFP- and AAV9-GLB1-injected organoids. Std,
monosialogangliosides used as standards. (F) Quantification
of GM1 content of AAV9-GFP–injected and AAV9-
GLB1–injected organoids by HPTLC. GM1 content was de-
termined by densitometry and normalized with the corre-
sponding phospholipid concentrations. Data represent mean
GM1 content of AAV9-GLB1–injected organoids relative to
AAV9-GFP–injected organoids± SD, n=3 lanes (⁎⁎p < .01,
t-test analysis between AAV9-GFP-injected and AAV9-GBL1-
injected values). (For interpretation of the references to
colour in this figure legend, the reader is referred to the web
version of this article.)
Y.L. Latour, et al. Molecular Genetics and Metabolism Reports 21 (2019) 100513
6
containing chloroform:methanol:0.25% CaCl2 (60:35:8, v:v:v) pre-
viously equilibrated for 1 h. Plates were allowed to dry completely and
then sprayed with 2% resorcinol, covered with glass, and baked at
125 °C for 10min.
Densitometry was performed to determine GM1 content using the
gel analysis tool in Fiji [45,46]. Relative GM1 content was determined
by normalizing the area under the GM1 peak to the corresponding total
phospholipid concentrations in the organic phase.
4.12. AAVrh9 injections
AAVrh9 (AAV9) vectors carrying the human β-gal gene (AAV9-
GLB1) or GFP (AAV9-GFP) were prepared as previously described [31].
Using a 32-gauge Hamilton 5 μl syringe (Hamilton), 1 μl of AAV9-GLB1
(3× 1013 vg/ml), or AAV9-GFP vector (3×1013 vg/ml) as control,
was injected into the center of each cerebral organoid at 10 weeks.
Organoids were cultured and analyzed 5weeks later, at 15 weeks. To
control for possible GFP expression during immunohistochemistry,
DAPI-only stained sections of AAV9-GFP-injected organoids were used
to set the threshold for background fluorescence to exclude GFP.
4.13. Statistics
Statistical analyses were performed using the Student's t-test or one-
way ANOVA to compare results between groups. P≤ .05 was con-
sidered statistically significant.
Supplementary data to this article can be found online at https://
doi.org/10.1016/j.ymgmr.2019.100513.
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